Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer
Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer
复制标题
DOI：
10.1002/bjs.5209
复制
发表时间：
2006-05-01
影响因子：
9.6
通讯作者：
Cormier, J. N.
中科院分区：
文献类型：
--
作者：
Xing, Y.;Foy, M.;Cormier, J. N.
背景：女性乳腺癌患者更常接受术前新辅助化疗。化疗后前哨淋巴结活检（SLNB）的可靠性尚未确定。这是一个荟萃分析的研究，检查结果SLNB术前chemotherapy.Methods：纳入的文章必须符合两个标准。首先，患者必须有可手术的乳腺癌，并在术前化疗后接受SLNB，其次，患者必须接受随后的腋窝淋巴结清扫术。进行荟萃分析，其中贝叶斯分层模型建立估计的识别率（IR）和SLNB在此setting.Results的敏感性：21项研究被确定，包括共1273例患者。报告的IR范围为72%至100%，合并估计为90%。SLNB的敏感性范围为67%至100%，合并估计为88（95%置信区间85至90%）。使用贝叶斯模型进行的荟萃分析结果显示，（后）估计IR和敏感性分别为91（95%可信区间88至94）和88（95%可信区间84至91）percentive.Conclusion：SLNB是一个可靠的工具，术前化疗后计划治疗。
Background: Women with breast cancer are more frequently being treated with preoperative neoadjuvant chemotherapy. The reliability of sentinel lymph node biopsy (SLNB) following chemotherapy has not been determined. This was a meta-analysis of studies that examined the results of SLNB after preoperative chemotherapy.Methods: Included articles had to meet two criteria. First, patients had to have had operable breast cancer and to have undergone SLNB after preoperative chemotherapy and, second, patients had to have undergone subsequent axillary lymph node dissection. Meta-analyses were performed in which Bayesian hierarchical models were created to estimate the identification rate (IR) and sensitivity of SLNB in this setting.Results: Twenty-one studies were identified that included a total of 1273 patients. The IRs reported ranged from 72 to 100 per cent, with a pooled estimate of 90 per cent. The sensitivity of SLNB ranged from 67 to 100 per cent, with a pooled estimate of 88 (95 per cent confidence interval 85 to 90) per cent. Meta-analyses performed using Bayesian modelling resulted in (posterior) estimates for IR and sensitivity of 91 (95 per cent credible interval 88 to 94) and 88 (95 per cent credible interval 84 to 91) per cent respectively.Conclusion: SLNB is a reliable tool for planning treatment after preoperative chemotherapy.